Furthermore, our study shows a significant reduction of neutrophil influx with anti-IL-33 that implies this therapy may be useful in additional chronic pulmonary disorders (COPD, IPF) that are often driven by an unregulated type 3 inflammatory profile involving excess levels of neutrophils. This evidence concerns the gene IL33 and idiopathic pulmonary fibrosis.